A retrospective analysis of biofilm antibiotic susceptibility testing: A better predictor of clinical response in cystic fibrosis exacerbations

Journal of Cystic Fibrosis

Volumn 8, Issue 2, 2009, Pages 122-127

  Keays, Tara ^a   Ferris, Wendy ^b   Vandemheen, Katherine L ^a   Chan, Francis ^b   Yeung, Sau Wai ^b   Mah, Thien Fah ^a   Ramotar, Karam ^a   Saginur, Raphael ^a   Aaron, Shawn D ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

Author keywords

Bacterial biofilms; Clinical outcomes; Cystic fibrosis; Microbiology

Indexed keywords

ANTIBIOTIC AGENT; CEFTAZIDIME; CIPROFLOXACIN; COTRIMOXAZOLE; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIUM ISOLATE; BIOFILM; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE EXACERBATION; FEMALE; HUMAN; LENGTH OF STAY; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTCOME ASSESSMENT; PROGNOSIS; RETROSPECTIVE STUDY; SPUTUM ANALYSIS; SURVIVAL; TREATMENT FAILURE;

ADULT; ANTI-BACTERIAL AGENTS; BIOFILMS; CYSTIC FIBROSIS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; RESPIRATORY TRACT INFECTIONS; RETROSPECTIVE STUDIES; SPUTUM; TREATMENT OUTCOME;

EID: 60449106108     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcf.2008.10.005     Document Type: Article

References (18)

1. Lechtzin N., John M., Irizarry R., Merlo C., Diette G.B., and Boyle M.P. Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa. Respiration 73 (2006) 27-33
2. Costerton J.W., Stewart P.S., and Greenberg E.P. Bacterial biofilms: a common cause of persistent infections. Science 284 (1999) 1318-1322
3. Stewart P.S. Mechanisms of antibiotic resistance in bacterial biofilms. Int J Med Microbiol 292 2 (2002) 107-113
4. Mah T., and O'Toole G. Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol. 9 1 (2001) 34-39
5. Mah T., Pitts B., Pellock B., Walker G., Stewart P.S., and O'Toole G.A. A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature 426 6964 (2003) 306-310
6. Lam J., Chan R., Lam K., and Costerton J.W. Production of mucoid microcolonies by Pseudomonas aeruginosa within infected lungs in cystic fibrosis. Infect Immun 28 2 (1980) 546-556
7. Singh P.K., Schaefer A.L., Parsek M.R., Moninger T.O., Welsh M.J., and Greenberg E.P. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 407 (2000) 762-764
8. Aaron S.D., Ferris W., Ramotar K., Vandemheen K., Chan F., and Saginur R. Single and combination antibiotic susceptibilities of planktonic, adherent, and biofilm-grown Pseudomonas aeruginosa isolates cultured from sputa of adults with cystic fibrosis. J Clin Microbiol 40 11 (2002) 4172-4179
9. Moskowitz S., Foster J., Emerson J., and Burns J. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol 42 5 (2004) 1915-1922
10. Hill D., Rose B., Pajkos A., Robinson M., Bye P., Bell S., et al. Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions. J Clin Microbiol 43 10 (2005) 5085-5090
11. Aaron S.D., Ferris W., Henry D.A., Speert D.P., and MacDonald N.E. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am J Respir Crit Care Med 161 4 (2000) 1206-1212
12. Aaron S.D., Vandemheen K., Ferris W., Fergusson D., Tullis E., Haase D., et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet 366 (2005) 463-471
13. Cystic Fibrosis Foundation. Microbiology and infectious disease in cystic fibrosis (1994), Bethesda, Maryland 1-26
14. Mahler D.A., Weinberg D.H., Wells C.K., and Feinstein A.R. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 85 (1984) 751-758
15. Ceri H., Olson M.E., Stremick C., Read R.R., Morck D., and Buret A. The Calgary biofilm device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 37 (1999) 1771-1776
16. Baltimore R.S., Christie C.D.C., and Smith G.J.W. Immunohistopathologic localization of Pseudomonas aeruginosa in lungs from patients with cystic fibrosis. Am Rev Respir Dis 140 (1989) 1650-1661
17. Caraher E., Reynolds G., Murphy P., McClean S., and Callaghan M. Comparison of antibiotic susceptibility of Burkholderia cepacia complex organisms when grown planktonically or as biofilm in vitro. Eur J Clin Microbiol Infect Dis 26 (2006) 213-216
18. Smith A., Fiel S.B., Mayer-Hamblett N., Ramsey B., and Burns J.L. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration. Lack of association in cystic fibrosis. Chest 123 5 (2003) 1495-1502